Last update 12 Jan 2026

SHR-7787

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
SHR-7787
Target
CD3 x DLL3
Action
inhibitors
Mechanism
CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), DLL3 inhibitors(Delta-like protein 3 inhibitors)
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication
Advanced Malignant Solid NeoplasmExtensive stage Small Cell Lung Cancer
Inactive Indication-
Originator Organization
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
Active Organization
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with SHR-7787
NCT07268040
/ RecruitingPhase 2
A Multicenter, Open-label Phase II Clinical Study of SHR-7787 Combined With Other Antitumor Drugs in Patients With Advanced Solid Tumors
NCT06605222
/ RecruitingPhase 1/2
A Phase I/II, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7787 in Patients With Advanced Solid Tumors
100 Clinical Results associated with SHR-7787
Login to view more data
100 Translational Medicine associated with SHR-7787
Login to view more data
100 Patents (Medical) associated with SHR-7787
Login to view more data
100 Deals associated with SHR-7787
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
China
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
23 Dec 2025
Extensive stage Small Cell Lung CancerIND Approval
China
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
22 Dec 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free